• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RXST

    RxSight Inc.

    Subscribe to $RXST
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: rxsight.com

    Recent Analyst Ratings for RxSight Inc.

    DatePrice TargetRatingAnalyst
    5/19/2025$25.00Equal Weight → Overweight
    Wells Fargo
    4/15/2025$18.00Neutral
    Piper Sandler
    4/9/2025$16.00Buy → Neutral
    UBS
    4/4/2025$40.00 → $17.00Overweight → Underweight
    Analyst
    4/3/2025$36.00 → $22.00Buy → Underperform
    BofA Securities
    12/20/2024$65.00 → $40.00Buy → Hold
    Stifel
    12/11/2024$56.00 → $42.00Overweight → Equal Weight
    Wells Fargo
    12/6/2024$52.00Buy
    UBS
    10/29/2024$72.00Buy
    Jefferies
    8/20/2024$54.00 → $66.00Buy
    Needham
    See more ratings

    RxSight Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Thunen Shelley B exercised 7,792 shares at a strike of $4.34, increasing direct ownership by 25% to 38,354 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      4/15/25 8:57:36 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Fountain Tamara sold $180,002 worth of shares (7,000 units at $25.71), decreasing direct ownership by 22% to 24,793 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      3/13/25 4:46:51 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Officer Weinberg Eric

      4 - RxSight, Inc. (0001111485) (Issuer)

      2/27/25 8:06:48 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Officer Goldshleger Ilya

      4 - RxSight, Inc. (0001111485) (Issuer)

      2/27/25 8:05:28 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Officer Thunen Shelley B

      4 - RxSight, Inc. (0001111485) (Issuer)

      2/27/25 8:04:17 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by President & CEO Kurtz Ronald M Md

      4 - RxSight, Inc. (0001111485) (Issuer)

      2/27/25 8:03:32 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Maniar Shweta sold $108,618 worth of shares (3,519 units at $30.87), decreasing direct ownership by 32% to 7,383 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      1/27/25 4:40:37 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Corley Jesse Anderson bought $100,004 worth of shares (3,210 units at $31.15) (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      1/17/25 7:08:42 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Officer Goldshleger Ilya exercised 3,105 shares at a strike of $15.08 and sold $143,078 worth of shares (3,105 units at $46.08) (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      12/3/24 6:38:23 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Maniar Shweta sold $173,518 worth of shares (3,782 units at $45.88), decreasing direct ownership by 26% to 10,902 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      11/26/24 7:26:50 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    RxSight Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RxSight upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded RxSight from Equal Weight to Overweight and set a new price target of $25.00

      5/19/25 8:47:30 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Piper Sandler initiated coverage on RxSight with a new price target

      Piper Sandler initiated coverage of RxSight with a rating of Neutral and set a new price target of $18.00

      4/15/25 9:02:26 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by UBS with a new price target

      UBS downgraded RxSight from Buy to Neutral and set a new price target of $16.00

      4/9/25 8:36:59 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by Analyst with a new price target

      Analyst downgraded RxSight from Overweight to Underweight and set a new price target of $17.00 from $40.00 previously

      4/4/25 8:39:56 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by BofA Securities with a new price target

      BofA Securities downgraded RxSight from Buy to Underperform and set a new price target of $22.00 from $36.00 previously

      4/3/25 8:25:00 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by Stifel with a new price target

      Stifel downgraded RxSight from Buy to Hold and set a new price target of $40.00 from $65.00 previously

      12/20/24 7:50:07 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded RxSight from Overweight to Equal Weight and set a new price target of $42.00 from $56.00 previously

      12/11/24 8:23:34 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • UBS initiated coverage on RxSight with a new price target

      UBS initiated coverage of RxSight with a rating of Buy and set a new price target of $52.00

      12/6/24 8:13:36 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Jefferies initiated coverage on RxSight with a new price target

      Jefferies initiated coverage of RxSight with a rating of Buy and set a new price target of $72.00

      10/29/24 6:29:51 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Needham reiterated coverage on RxSight with a new price target

      Needham reiterated coverage of RxSight with a rating of Buy and set a new price target of $66.00 from $54.00 previously

      8/20/24 8:59:40 AM ET
      $RXST
      Ophthalmic Goods
      Health Care

    RxSight Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Corley Jesse Anderson bought $100,004 worth of shares (3,210 units at $31.15) (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      1/17/25 7:08:42 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Corley Jesse Anderson bought $1,014,570 worth of shares (22,476 units at $45.14), increasing direct ownership by 18% to 38,438 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      11/14/24 7:14:14 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Tammenoms Bakker Juliet bought $305,456 worth of shares (5,000 units at $61.09), increasing direct ownership by 17% to 34,840 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      5/21/24 4:11:17 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Tammenoms Bakker Juliet bought $406,673 worth of shares (8,000 units at $50.83), increasing direct ownership by 37% to 29,840 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      2/15/24 4:15:46 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    RxSight Inc. SEC Filings

    See more
    • SEC Form SD filed by RxSight Inc.

      SD - RxSight, Inc. (0001111485) (Filer)

      5/20/25 4:30:10 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by RxSight Inc.

      10-Q - RxSight, Inc. (0001111485) (Filer)

      5/7/25 4:15:25 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RxSight, Inc. (0001111485) (Filer)

      5/7/25 4:10:09 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form DEF 14A filed by RxSight Inc.

      DEF 14A - RxSight, Inc. (0001111485) (Filer)

      4/21/25 4:30:18 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form DEFA14A filed by RxSight Inc.

      DEFA14A - RxSight, Inc. (0001111485) (Filer)

      4/21/25 4:30:04 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form SCHEDULE 13G filed by RxSight Inc.

      SCHEDULE 13G - RxSight, Inc. (0001111485) (Subject)

      4/8/25 8:23:23 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 144 filed by RxSight Inc.

      144 - RxSight, Inc. (0001111485) (Subject)

      3/12/25 4:02:34 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form S-8 filed by RxSight Inc.

      S-8 - RxSight, Inc. (0001111485) (Filer)

      2/25/25 4:54:13 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 10-K filed by RxSight Inc.

      10-K - RxSight, Inc. (0001111485) (Filer)

      2/25/25 4:15:33 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RxSight, Inc. (0001111485) (Filer)

      2/25/25 4:10:09 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    RxSight Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/14/24 5:46:12 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 4:50:57 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 9:40:27 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/4/24 1:52:52 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by RxSight Inc. (Amendment)

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      2/14/24 5:01:36 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G filed by RxSight Inc.

      SC 13G - RxSight, Inc. (0001111485) (Subject)

      2/14/24 7:54:29 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G filed by RxSight Inc.

      SC 13G - RxSight, Inc. (0001111485) (Subject)

      2/12/24 6:19:49 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13D/A filed by RxSight Inc. (Amendment)

      SC 13D/A - RxSight, Inc. (0001111485) (Subject)

      8/18/23 4:18:01 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13D/A filed by RxSight Inc. (Amendment)

      SC 13D/A - RxSight, Inc. (0001111485) (Subject)

      6/5/23 4:52:50 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by RxSight Inc. (Amendment)

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      2/14/23 4:55:20 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    RxSight Inc. Financials

    Live finance-specific insights

    See more

    RxSight Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

      ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 8740296. The call will also be broadcast live in listen-only mode via a link on the company's investor relations web

      4/23/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

      ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. Preliminary First Quarter 2025 Results Preliminary first quarter 2025 revenue is expected to be approximately $37.9 million, representing growth of 28% compared to the prior year period, and a decrease of 6% compared to the fourth quarter of 2024, driven by: The sale

      4/2/25 8:00:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance

      ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 31, 2024. Key Quarterly and Full-Year Highlights Recognized fourth quarter 2024 revenue of $40.2 million, an increase of 41% compared to the fourth quarter of 2023, reflecting: The sale of 29,069 Light Adjustable Lenses (LAL™/LAL+®), representing an 61% increase in procedure volume compared to the fourth quarter of 2023; andThe sale of 83 Light Delivery Devices (LDD™s), expanding the installed base to

      2/25/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025

      ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024 after the market close on Tuesday, February 25, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 7159871. The call will also be broadcast live in listen-only mode via a link on the company's investor r

      2/11/25 4:10:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports Third Quarter 2024 Financial Results

      ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights Reported third quarter 2024 revenue of $35.3 million, an increase of 59% compared to the third quarter of 2023, reflecting: The sale of 24,554 Light Adjustable Lenses (LAL™/LAL+™), representing an 80% increase in procedure volume compared to the third quarter of 2023; andThe sale of 78 Light Delivery Devices (LDD™s), representing a 18% increase in unit sales compared to

      11/7/24 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024

      ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (888) 596-4144 or (646) 968-2525, and enter the conference code: 7406253. The call will also be broadcast live in listen-only mode via a link on the company's investor re

      10/24/24 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024

      ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call please register here. While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applicati

      7/22/24 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports First Quarter 2024 Financial Results

      ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+™), representing a 92% increase in procedure volume compared to the first quarter of 2023;The sale of 66 Light Delivery Devices (LDD™s), representing an 18% increase in unit sales compar

      5/6/24 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024

      ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call please register here. While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applications are

      4/22/24 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum

      ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Stifel Virtual Ophthalmology Forum. RxSight's management is scheduled to participate in a fireside chat on Tuesday, May 27, 2025, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin

      5/20/25 4:10:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Present at the Bank of America Healthcare Conference

      ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas. RxSight's management is scheduled to present on Wednesday, May 14, 2025, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized visio

      4/30/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

      ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 8740296. The call will also be broadcast live in listen-only mode via a link on the company's investor relations web

      4/23/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

      ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. Preliminary First Quarter 2025 Results Preliminary first quarter 2025 revenue is expected to be approximately $37.9 million, representing growth of 28% compared to the prior year period, and a decrease of 6% compared to the fourth quarter of 2024, driven by: The sale

      4/2/25 8:00:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

      ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. RxSight's management is scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedic

      3/25/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance

      ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 31, 2024. Key Quarterly and Full-Year Highlights Recognized fourth quarter 2024 revenue of $40.2 million, an increase of 41% compared to the fourth quarter of 2023, reflecting: The sale of 29,069 Light Adjustable Lenses (LAL™/LAL+®), representing an 61% increase in procedure volume compared to the fourth quarter of 2023; andThe sale of 83 Light Delivery Devices (LDD™s), expanding the installed base to

      2/25/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025

      ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024 after the market close on Tuesday, February 25, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 7159871. The call will also be broadcast live in listen-only mode via a link on the company's investor r

      2/11/25 4:10:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance

      ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance. Preliminary Unaudited Fourth Quarter and Full-year 2024 Results Preliminary unaudited fourth quarter 2024 revenue is expected to be approximately $40.2 million, representing growth of approximately 41% compared to the prior year period, driven by: The sale of 29,069 Light Adjustable Lenses (LAL™/LAL+®); representing a

      1/12/25 9:30:00 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

      ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference. RxSight's management is scheduled to present on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients follow

      1/2/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    RxSight Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors

      ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig

      1/4/22 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care